Black Hawk Acquisition Corp: shareholder votes at Oct 13, 2026 meeting

What happened

• Black Hawk Acquisition Corporation reported that it held an extraordinary general meeting of shareholders on Oct 13, 2026. Shareholders approved the Business Combination Agreement with Vesicor Therapeutics, Inc., the transfer of the company by way of continuation out of the Cayman Islands and domestication in Delaware, adoption of proposed certificate of incorporation and bylaws, election of five directors, Nasdaq issuance approval, the Vesicor Therapeutics Holdings, Inc. 2026 Equity Incentive Plan, amendment to remove the $5,000,001 net tangible assets requirement, and an adjournment authority.

Key details

• Record date: Sep 1, 2026. Ordinary shares issued and outstanding as of the record date: 4,153,577. Shares present or represented by proxy at the meeting: 3,211,516 (77.3%).
• Business Combination, domestication, organizational documents and director elections: For 3,191,351; Against 20,165; Abstain 0. Nasdaq proposal: For 3,191,352; Against 20,164; Abstain 0.
• Incentive plan: For 3,102,603; Against 20,164; Abstain 88,749. Adjournment: For 3,141,351; Against 70,165; Abstain 0.
• Director nominees elected: Luo Feng, Warren Hosseinion, Frederick Woodruff Field, Oded Levy, Qi Ouyang (each: For 3,191,351; Against 20,165; Abstain 0).
• Redemption activity: Holders of 2,089,162 ordinary shares exercised redemption rights for an aggregate of $25,153,510.48, at approximately $12.04 per share. The company is not permitting reversals of redemption elections.
• The company intends to file an amendment to its amended and restated memorandum and articles of association with the Registrar of Companies of the Cayman Islands promptly following the meeting.

Why it may matter

• The filing reports Item 5.07: submission of matters to a vote of security holders, which covers the shareholder votes and the redemption activity reported above. This filing does not show why the insider traded or why the company acted.